List view / Grid view
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
![robotic hand pipetting from petri dish of organoids next to a clock - idea of automation speeding up organoid development [Credit: Daria Sokol/MIPT Press Office].](https://www.drugtargetreview.com/wp-content/uploads/algorithm-accelerating-organoid-development.jpg)
The semi-automated process enabled researchers to make retinal organoid production and selection nearly four times faster.
According to a new study, the SARS-CoV-2 virus is accumulating genetic mutations, including one called D614G which may have made it more contagious.
Binding of SARS-CoV-2 spike proteins to the brain’s endothelial cells can cause the blood-brain barrier to become leaky, potentially causing the neurological symptoms associated with COVID-19.
Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
A new study has highlighted the advantages of using flow cytometry for the analysis of neuroimmune cell populations from mouse models.
A new report has said that by 2023, the flow cytometry market will be worth $8.88 billion, partly due to an increase in stem cell research.
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
Study reveals which neurons are most affected by epilepsy, presenting novel targets for seizure drug discovery and development.
New findings suggest that late-onset Alzheimer's Disease (AD) is driven by epigenetic changes in the brain.
Scientists reveal that some patients who develop severe COVID-19 symptoms mount ineffective immune responses due to a lack of type I interferons, either through genetic mutation or inactivation by auto-reactive antibodies.
Inhaled general anaesthetics have been used for over 100 years and continue to be used daily for surgeries around the world. But how do they induce changes to consciousness? This article explores the research that suggests the anaesthetics chloroform and isoflurane disrupt the organisation of lipid rafts within cellular membranes…
The detailed analysis of adenosquamous cancer of the pancreas (ASCP) suggested FGFR and RORC were two promising therapeutic targets.
IN NOVEMBER 2017, leadXpro chose to strengthen its capabilities with the Creoptix™ WAVEsystem. “We were looking for a label‑free, biophysical method to investigate binding affinity and kinetics of small molecules with challenging integral membrane proteins,” explained Michael Hennig, Chief Executive Officer of leadXpro.
We have entered a new era of drug discovery where the use of advanced cell models such as multi-cellular co-cultures, stem cells and CRISPR-based screens can lead to the next generation of therapeutics.
